Solara Active Pharma Sciences Limited — Updates, 25-07-2025: Press Release

Solara Active Pharma Sciences reported strong Q1 FY26 results. Revenue grew 15% QoQ to 320.1 Cr. Gross Margin expanded to 54.1%, driven by profitable products and regulated market focus (77% of revenue). EBITDA increased 13% QoQ to 57.5 Cr, leading to a positive PAT of 10.5 Cr, highest in over 12 quarters. The company reduced gross debt by 143.3 Cr to 632.7 Cr. Additionally, Solara plans to demerge its CRAMS and Polymers business into a new entity. This strategic move will transfer 200 Cr debt, significantly strengthening the legacy API business balance sheet with a projected Net Debt to EBITDA below 1x.